DHR

220.3603.16%
JG

Jose-Carlos Gutierrez-Ramos

Independent Non-Executive Director and Member of Research & Innovation Advisory Board

Dr. Jose-Carlos Gutierrez-Ramos, also known as JC, Ph.D., is Director of Repertoire Immune Medicines, Inc. Dr. Gutierrez-Ramos is Director of Genomics PLC from January 2025. He is Member of Scientific Advisory Board of Minovia Therapeutics LTD. He serves as the Chief Science Officer at Danaher Corporation since April 2021 and serves as its Senior Vice President since December 2020. Dr. Gutierrez-Ramos served as Chief Scientific Officer at Danaher Corporation since December 2020 until April 2021. Dr. Gutierrez-Ramos serves as Independent Non-Executive Director and Member of Research & Innovation Advisory Board at Bicycle Therapeutics plc since March 17, 2021 and served as its Chair of scientific Advisory Board and Member of Scientific Advisory Board since May 31, 2018 until June 2020. He served as Advisor at Synlogic, Inc. since May 10, 2018. He served as Independent Director of Oryzon Genomics S.A. since February 2018 until February 21, 2020. He was the Chief Executive Officer of Synlogic, Inc. from 2015 until May 10, 2018 and was its President until May 10, 2018. Dr. Gutiérrez-Ramos had been Independent Director at Evelo Biosciences, Inc. since April 01, 2022 until November 20, 2023 and served as on the Board from June 2019 to February 2020. Dr. Gutierrez-Ramos served as Group Vice President of Biotherapeutics R&D at Pfizer Inc., until May 2015 and former group senior vice president and global head of bio therapeutics research at Pfizer. Dr. Gutierrez-Ramos served as the Chief Scientific Officer of Avidia, Inc. and served as its Senior Vice President of Research & Non-Clinical Development since August 2006. Dr. Gutierrez-Ramos served as the Chief Scientific Officer and Vice President of Research and Development of Peptimmune, Inc. and was responsible for the development of peptide-based therapeutics for autoimmune diseases including multiple sclerosis and diabetes. He is a highly regarded Scientist with significant expertise in Immunology and product development. He served as Chief Scientific Officer of a Spanish biotechnology company, Genetrix, where he led the spin out of several technologies from the Spanish Research Council. Dr. Gutierrez-Ramos served as Vice President of Inflammation of Millennium Pharmaceuticals, where he led a group of more than 100 scientists. Importantly, he was responsible for advancing preclinical candidates in Immunology to human trials and advancing compounds through clinical development. Dr. Gutierrez-Ramos served as an Assistant Professor of Medicine at the Harvard Medical School, where he led a major research team at the Center for Blood Research. Prior to working in the private sector, Dr. Gutierrez-Ramos was a tenure track professor at Harvard Medical School in the Department of Genetics. He served as Director of Momenta Pharmaceuticals Inc. since March 9, 2016 until October 01, 2020. He serves as a Member of Scientific Advisory Board at DecImmune Therapeutics Inc. He was a Director of Synlogic, Inc. until May 10, 2018. Prior to Danaher, he served as the Head of Global Drug Discovery at AbbVie Inc. and Senior Vice President and CEDD Head of Immuno Inflammation at GlaxoSmithKline plc. He was the founding CEO and President at Repertoire Immune Medicine, where he built and led a team to decode the human immunome. As a biotech leader or in global positions, he oversaw multiple drug discovery teams, resulting in five marketed drugs. He previously served in a series of progressively more responsible research and development roles at Avidia (acquired by Amgen Inc.) and Millennium Pharmaceuticals, Inc. (acquired by Takeda Oncology). Dr. Gutierrez-Ramos was a Member of the prestigious Basel Institute for Immunology in Basel, Switzerland and a fellow at the Max-Planck Institute of Immunobiology in Freiburg, Germany. He was also a professor for the Spanish Scientific Research Council (CSIC) at the National Center of Biotechnology in Madrid, Spain. He was a scientist and member at the prestigious Basel Institute for Immunology in Basel, Switzerland and a Postdoctoral Fellow at the Max Plank Institute for Immunbiologie in Freiburg, Germany. Dr. Gutierrez-Ramos received a Bachelor of Science Degree, summa cum laude, in Chemistry with a minor in Biochemistry from Universidad Complutense de Madrid. He earned his M.S. in Chemistry and his Ph.D. in Immunology/immunochemistry from the Autonoma University of Madrid, Spain in 1989. in 1989.

Positions